Cancer Genetics (NASDAQ:CGIX) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Cancer Genetics (NASDAQ:CGIX) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the stock.

Cancer Genetics Price Performance

Shares of CGIX stock opened at $0.18 on Tuesday. Cancer Genetics has a 1 year low of $2.11 and a 1 year high of $17.50. The business’s 50 day moving average is $0.26. The firm has a market capitalization of $725,291.75, a price-to-earnings ratio of -0.09 and a beta of 2.72.

About Cancer Genetics

Vyant Bio, Inc is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson’s Disease.